Some of these opportunities and risks include:

• New business models and optimized operations through predictive models and machine learning
• Widespread adoption of business platform technologies that are expanding industry boundaries to create collaborative, integrated, and innovation-driven ecosystems
• Continuous threats from high capital costs, fluctuating raw material prices, volatile geopolitical climates, mass commoditization, and an overwhelming amount of regulations

In a perfect world, confronting these challenges would be as simple as embedding intelligence, such as machine learning, into business systems and processes. Unfortunately, today’s industry realities require so much more – namely, new sources of value and unique skills that can transform the value chain and business models.

There is so much at stake throughout the industry. But for many 51·çÁ÷customers, the 51·çÁ÷Model Company service for Chemicals is accelerating and simplifying the path to competitive business transformation.

What Is 51·çÁ÷Model Company for Chemicals?

51·çÁ÷Model Company for Chemicals is a collection of insights, knowledge, and lessons learned, acquired through decades of experience in working with companies from the chemicals industry. The service is an evolving portfolio of the latest reference solutions, industry best practices, and master data – all designed to provide the knowledge and skills that chemicals businesses need to optimize end-to-end processes and sharpen decision-making.

Click the button below to load the content from YouTube.

Always allow YouTube

For many customers, 51·çÁ÷Model Company for Chemicals is a critical component in their accelerated conversion to 51·çÁ÷S/4HANA. The service boasts a library of model company offerings that covers a large variety of core processes. It also allows customers to experiment and test new use cases in order to inspire innovative change in areas such as product development, safety, and stewardship; manufacturing and procurement; sales, logistics, and asset management; and IT monitoring. Industry-specific topics are also supported, especially batch traceability, active ingredients subcontracting, quality control, and regulatory compliance.

51·çÁ÷Model Company for Chemicals is also helping  customers reimagine their operational processes. By providing a blueprint for choosing and implementing the right intelligent technologies and analytics capabilities for their businesses, customers are experiencing considerable changes in product safety and stewardship as well as tank-level monitoring.

As new innovations continue to be added to the model company portfolio, more efficient practices are introduced into functions such as compliance, sales, management of safety data sheets, and dangerous goods management.

Rediscover Your Edge with Unprecedented Business Value and Intelligence

The beauty of 51·çÁ÷Model Company for Chemicals is the potential to turn every business improvement into an opportunity that will shape success for years to come. Whether streamlining existing processes, optimizing decision-making, boosting revenue and profits, improving customer satisfaction, or capitalizing on emerging opportunities, chemical companies can set the priorities that drive the right changes with the right digital tools.

Stay in the conversation by following the 51·çÁ÷Services and Support offerings on ,Ìý, , and .

Maurice Carl Zettel is a business process consultant for 51·çÁ÷Digital Business Services.

However, as patients become more proactive and involved in their wellness and providers face new market and regulatory expectations, the industry’s playbook is evolving – continuously, at an ever-accelerating pace.

Now, in addition to commercialization and profitability, they are at the front lines of patient safety and experience. From the globalization of drug supply chains to the competing alternatives for treatment or care and rising threats from counterfeit and fraudulent medicine, the role of pharmaceutical companies has never been more important.

So how can pharmaceutical companies work faster and smarter to relentlessly pursue proven solutions, meaningful provider relationships, and personalized patient outcomes? For many 51·çÁ÷customers in the industry, reliance on the 51·çÁ÷Model Company service for Pharmaceuticals is illuminating strategic priorities and new opportunities.

What Is 51·çÁ÷Model Company for Pharmaceuticals?

Using insights and knowledge acquired from long-term experience within the pharmaceutical industry, 51·çÁ÷has developed a portfolio of reference solutions and content called 51·çÁ÷Model Company for Pharmaceuticals.

Click the button below to load the content from YouTube.

Always allow YouTube

The service is prepackaged with 51·çÁ÷S/4HANA, ready to be used across end-to-end processes, and based on the latest industry best practices and master data. It delivers business value within two to four weeks by providing an advanced IT architecture and the highest degree of standardization in order to lower implementation risks and build a future-proof digital foundation.

For most customers, 51·çÁ÷Model Company for Pharmaceuticals is a critical component in their accelerated conversion to 51·çÁ÷S/4HANA. Interoperable with a library of model company offerings available through SAP, the service covers a large variety of core processes. It also allows hands-on experiences to experiment and test new use cases. These capabilities have inspired innovation for business areas, including product development, manufacturing, procurement, sales, logistics, and asset management. Industry-specific concerns are also addressed, such as batch traceability, active ingredients subcontracting, quality control, and regulatory compliance.

Additionally, 51·çÁ÷Model Company for Pharmaceuticals allows customers to innovate their operational processes by leveraging intelligent technologies and analytics capabilities. Doing so can drive considerable changes in product safety and stewardship and tank-level monitoring. As new innovations are added to the model company portfolio, new opportunities for improvement will introduce more efficient practices for functions such as compliance, sales, management of safety data sheets, and advanced track-and-trace capabilities.

Find Your Place in a World Where the rules of Patient Care Always Change

The ability to respond to patient expectations, provider demands, and government requirements will determine the winners in the pharmaceutical industry – in 2020 and beyond. Successful business model innovation, process optimization, and workforce productivity will always be inextricably linked to great patient, customer, and employee experiences.

Luckily, 51·çÁ÷Model Company for Pharmaceuticals is designed to help businesses pull away from the competition and widen the performance gap with each new innovation. By creating a landscape of exceptional experiences and patient assurance, customers can kickstart a new era of profitability with new technologies, practices, and methodologies that help deliver lifesaving products and services more efficiently.

Stay in the conversation by following 51·çÁ÷Services and Support on
,Ìý, , and .

Maurice Carl Zettel is a business process consultant for 51·çÁ÷Digital Business Services.